Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Mechanism-Based Inhibitory and Peroxisome Proliferator-Activated Receptor α–Dependent Modulating Effects of Silybin on Principal Hepatic Drug-Metabolizing Enzymes

Hong Wang, Tingting Yan, Yuan Xie, Min Zhao, Yuan Che, Jun Zhang, Huiying Liu, Lijuan Cao, Xuefang Cheng, Yang Xie, Feiyan Li, Qu Qi, Guangji Wang and Haiping Hao
Drug Metabolism and Disposition April 2015, 43 (4) 444-454; DOI: https://doi.org/10.1124/dmd.114.061622
Hong Wang
State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tingting Yan
State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuan Xie
State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min Zhao
State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuan Che
State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Zhang
State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huiying Liu
State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lijuan Cao
State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuefang Cheng
State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yang Xie
State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Feiyan Li
State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qu Qi
State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guangji Wang
State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haiping Hao
State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Hepatic distribution of silybin in mice. Mice were orally administrated with silybin (50 mg/kg/d and 150 mg/kg/d, once daily) for a consecutive 14 days. The livers were collected at indicated time points (5 mice per time point) after the last administration. Exposure of silybin in livers was analyzed by a liquid chromatography tandem mass spectrometry system. The data are expressed as mean ± S.D.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    The mRNA levels of principal P450s (A) and UGTs (B) in mice liver samples. Mice were intragastrically treated with 50 mg/kg or 150 mg/kg silybin for 2 weeks once per day. Twenty-four hours after the last administration, mice were sacrificed and the livers were immediately removed. The mRNA levels of Cyp1a2, Cyp2c29, Cyp2e1, Cyp3a11, Ugt1a1, Ugt1a6, Ugt1a7, Ugt1a9, and Ugt2b were determined via reverse-transcriptase PCR analysis; glyceraldehyde-3-phosphate dehydrogenase was used as an internal standard to normalize all samples.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Protein levels of principal P450s (A) and UGTs (B) in mice liver samples. Protein levels of CYP1A2, CYP2C, CYP2E1, CYP3A11, UGT1A1, UGT1A6, UGT1A, and UGT2B were determined via Western blot analysis; glyceraldehyde-3-phosphate dehydrogenase was used as an internal standard to normalize all samples.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Mechanism-based inhibition of P450s by silybin in MLM. In NADPH-dependent inhibitory assays, 100 μM silybin was incubated with normal mouse liver microsomes in the presence or absence of NADPH-generating system. In time- and concentration-dependent inhibitory assays, silybin (0, 10, 50, and 100 μM) was preincubated for different periods (0, 2, 4, and 8 minutes) in the presence of NADPH, followed by incubation with each probe substrate. The remaining enzyme activities were then determined, as described in Materials and Methods. The kobs was obtained from the slop of the individual lines, and these slops were fit to a Kitz-Wilson plot (inset). (A) CYP3A11, (B) CYP2C, (C) CYP1A2.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Mechanism-based inhibition of P450s by silybin in HLM. In NADPH-dependent inhibitory assays, 100 μM silybin was incubated with normal mouse liver microsomes in the presence or absence of NADPH-generating system. In time- and concentration-dependent inhibitory assays, silybin (0, 10, 50, and 100 μM) was preincubated for different periods (0, 2, 4, and 8 minutes) in the presence of NADPH, followed by incubation with each probe substrate. The remaining enzyme activities were then determined, as described in Materials and Methods. The kobs was obtained from the slop of the individual lines, and these slops were fit to a Kitz-Wilson plot (inset). (A) CYP3A4/5, (B) CYP2C9, (C) CYP1A2.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Mechanism-based inactivation (A, B) and competitive inhibition (C, D) of silybin on UGT1A1. Silybin was preincubated in normal mouse (A) and human (B) liver microsomes for 0.5 hour before the enzyme activity assay of UGT1A1 in the presence or absence of NADPH-generating system. Data are expressed as percentage of control, and bars represent mean ± S.D. (n = 3). *P < 0.05, compared with control group (with or without NADPH, respectively). #P < 0.05, ##P < 0.01, compared with relative group treated with the same dose of silybin without NADPH. Silybin was coincubated with β-estradiol in normal mouse liver microsomes (C) and human liver microsomes (D). Double reciprocal plots for the kinetics of inhibition of β-estradiol glucuronidation by silybin in normal mouse liver microsomes.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Effect of silybin on PPARα signal. (A) mRNA levels of Pparα and its target genes (L-Fabp and Acox1) in the liver of mice treated with silybin. Mice were treated with 50 mg/kg or 150 mg/kg silybin for 2 weeks. The mRNA levels of Pparα, L-Fabp, and Acox1 were determined via reverse-transcriptase PCR analysis. (B) The mRNA levels of PPARα and L-FABP and (C) luciferase activities of PPARα in HepG2 cells treated with silybin or fenofibrate. HepG2 cells were treated with dimethylsulfoxide (0.1%), silybin (25 and 50 μM), or fenofibrate (50 μM) for 24 hours. Cells were then collected for reverse-transcriptase PCR assay and reporter gene assays. *P < 0.05, **P < 0.01, ***P < 0.001 compared with respective control.

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    Computational molecular docking of silybin and fenofibrate to the ligand binding domain of PPARα. (A) Chemical structure of silybin and fenofibrate. The conformer with least energy for silybin or fenofibrate was chosen for subsequent docking. Crystal structure of human PPARα was obtained from Protein Data Bank, and the docking analysis was conducted by DISCOVERY STUDIO. Repeated dockings were carried out until no further refinement in clustering or binding energy of conformer was achieved. Based on population size and binding energy, the best conformation was chosen for further analysis. Amino acid residues predicted to interact with the ligands are shown (B).

  • Fig. 9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 9.

    Effect of silybin on PPARα activation in the presence or absence of fenofibrate in HepG2 cells. HepG2 cells were treated with dimethylsulfoxide (0.1%) or silybin (25 and 50 μM) in the presence or absence of fenofibrate (50 μM) for 24 hours. Cells were then collected to detect the mRNA level of PPARα (A) and L-FABP (B), as well as the luciferase activities of PPARα (C). ***P < 0.001 compared with dimethylsulfoxide (vehicle) group; ###P < 0.001 compared with fenofibrate group.

  • Fig. 10.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 10.

    Effect of silybin on PPARα activation in the presence or absence of fenofibrate in mice. C57BL/6 mice were treated with vehicle or silybin (50 and 150 mg/kg) together with or without fenofibrate (100 mg/kg) for a consecutive 14 days. Twenty-four hours after the last administration, the mice were sacrificed and their livers were immediately removed. mRNA levels of Pparα (A), L-Fabp (B), and Acox1 (C) were determined via reverse-transcriptase PCR analysis; glyceraldehyde-3-phosphate dehydrogenase was used as an internal standard to normalize all samples. ***P < 0.001 compared with dimethylsulfoxide (vehicle) group; ##P < 0.01, ###P < 0.001 compared with fenofibrate group.

  • Fig. 11.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 11.

    Effect of coadministration of silybin and fenofibrate on the expression and activity UGT1A6. (A) mRNA levels of UGT1A6 in HepG2 cells. After being treated with dimethylsulfoxide (0.1%) or silybin (25 and 50 μM) in the presence or absence of fenofibrate (50 μM) for 24 hours, HepG2 cells were collected for reverse-transcriptase PCR assay. (B) mRNA levels and (C) activities of Ugt1a6 in the livers of mice. C57BL/6 mice were treated with vehicle or silybin (50 and 150 mg/kg) together with or without fenofibrate (100 mg/kg) for a consecutive 14 days. Twenty-four hours after the last administration, the mice were sacrificed and their livers were immediately removed to detect the mRNA levels and activities of UGT1A6. Glyceraldehyde-3-phosphate dehydrogenase was used as an internal standard to normalize all samples in reverse-transcriptase PCR analysis. *P < 0.05 compared with dimethylsulfoxide (vehicle) group; #P < 0.05 compared with fenofibrate group.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Enzyme activities of main DMEs

    Mice were treated with silybin (50 mg/kg or 150 mg/kg, once daily) for a consecutive 2 weeks. Twenty-four hours after the last administration, the mice were sacrificed and their livers were immediately removed to prepared microsomes. Enzyme activities of main P450s and UGTs were tested using the typical probe substrate approach. Data are shown as mean ± S.D. (n = 3).

    SubstratesActivity of DMEs (pmol/min/mg microsome protein)
    VehicleSilybin (50 mg/kg)Silybin (150 mg/kg)
    Phenacetin516.23 ± 79.93440.59 ± 33.02319.10 ± 27.71a
    Diclofenac159.06 ± 4.39168.32 ± 8.92126.97 ± 1.51a
    Chlorzoxazone1446.31 ± 29.981553.31 ± 59.821332.36 ± 81.52
    Midazolam1291.11 ± 98.691305.59 ± 29.69907.76 ± 60.01b
    β-estradiol718.71 ± 42.12621.71 ± 16.36a419.42 ± 21.95b
    4-MU75,459.46 ± 9478.70109,474.65 ± 2324.0283,348.31 ± 8070.37
    Naloxone286.74 ± 38.05295.84 ± 31.74289.04 ± 29.78
    • ↵a P < 0.01 represents the comparison of activities of DMEs between Silybin treated groups and vehicle group.

    • ↵b P < 0.001.

Additional Files

  • Figures
  • Tables
  • Data Supplement

    Files in this Data Supplement:

    • Supplemental Data -

      Supplemental Table 1 - List of primer sequences used for RT-PCR

      Supplemental Figure 1 - Effects of co-administration of silybin and fenofibrate on the mRNA levels of UGTs in HepG2 cells

      Supplemental Figure 2 - mRNA levels of Ugt isozymes in the livers of mice treated with silybin and/or fenofibrate

      Supplemental Figure 3 - Activities of Ugt isozymes in the livers of mice treated with silybin and/or fenofibrate

      Supplemental Figure 4 - Activities of main P450s in the livers of mice treated with silybin for only once

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 43 (4)
Drug Metabolism and Disposition
Vol. 43, Issue 4
1 Apr 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mechanism-Based Inhibitory and Peroxisome Proliferator-Activated Receptor α–Dependent Modulating Effects of Silybin on Principal Hepatic Drug-Metabolizing Enzymes
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Regulatory Effects of Silybin on DMEs

Hong Wang, Tingting Yan, Yuan Xie, Min Zhao, Yuan Che, Jun Zhang, Huiying Liu, Lijuan Cao, Xuefang Cheng, Yang Xie, Feiyan Li, Qu Qi, Guangji Wang and Haiping Hao
Drug Metabolism and Disposition April 1, 2015, 43 (4) 444-454; DOI: https://doi.org/10.1124/dmd.114.061622

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Regulatory Effects of Silybin on DMEs

Hong Wang, Tingting Yan, Yuan Xie, Min Zhao, Yuan Che, Jun Zhang, Huiying Liu, Lijuan Cao, Xuefang Cheng, Yang Xie, Feiyan Li, Qu Qi, Guangji Wang and Haiping Hao
Drug Metabolism and Disposition April 1, 2015, 43 (4) 444-454; DOI: https://doi.org/10.1124/dmd.114.061622
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Candesartan glucuronide serves as a CYP2C8 inhibitor
  • Role of AADAC on eslicarbazepine acetate hydrolysis
  • Gene expression profile of human intestinal epithelial cells
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics